AU2017213844A1 - Anti-ROR1 antibodies and uses thereof - Google Patents

Anti-ROR1 antibodies and uses thereof Download PDF

Info

Publication number
AU2017213844A1
AU2017213844A1 AU2017213844A AU2017213844A AU2017213844A1 AU 2017213844 A1 AU2017213844 A1 AU 2017213844A1 AU 2017213844 A AU2017213844 A AU 2017213844A AU 2017213844 A AU2017213844 A AU 2017213844A AU 2017213844 A1 AU2017213844 A1 AU 2017213844A1
Authority
AU
Australia
Prior art keywords
ser
leu
gly
pro
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017213844A
Other languages
English (en)
Inventor
Ashwini BALAKRISHNAN
Benjamin G. Hoffstrom
Julie RANDOLPH-HABECKER
Stanley R. Riddell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of AU2017213844A1 publication Critical patent/AU2017213844A1/en
Assigned to FRED HUTCHINSON CANCER CENTER reassignment FRED HUTCHINSON CANCER CENTER Request for Assignment Assignors: FRED HUTCHINSON CANCER RESEARCH CENTER
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017213844A 2016-02-02 2017-02-02 Anti-ROR1 antibodies and uses thereof Abandoned AU2017213844A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662290337P 2016-02-02 2016-02-02
US62/290,337 2016-02-02
US201662324876P 2016-04-19 2016-04-19
US62/324,876 2016-04-19
PCT/US2017/016300 WO2017136607A1 (en) 2016-02-02 2017-02-02 Anti-ror1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2017213844A1 true AU2017213844A1 (en) 2018-08-02

Family

ID=58054529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017213844A Abandoned AU2017213844A1 (en) 2016-02-02 2017-02-02 Anti-ROR1 antibodies and uses thereof

Country Status (9)

Country Link
US (3) US10968275B2 (https=)
EP (2) EP4006056A1 (https=)
JP (2) JP7029401B2 (https=)
CN (1) CN108699149B (https=)
AU (1) AU2017213844A1 (https=)
CA (1) CA3012827A1 (https=)
ES (1) ES2903228T3 (https=)
MX (1) MX2018009011A (https=)
WO (1) WO2017136607A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2818103T3 (es) 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
EP4006056A1 (en) 2016-02-02 2022-06-01 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
EP3936523A4 (en) * 2019-01-08 2022-09-07 Shenzhen University DETECTION OF ANTIBODIES AGAINST MALIGNANT TUMOR CELLS AND THEIR USES
SG11202107976SA (en) 2019-01-29 2021-08-30 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
CN118974090A (zh) * 2022-04-02 2024-11-15 山东先声生物制药有限公司 抗ror1的抗体及其用途
KR20240016216A (ko) * 2022-07-26 2024-02-06 (주)에임드바이오 항-ror1 항체 및 이의 용도
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN115894691B (zh) * 2022-12-27 2026-03-03 上海医药集团生物治疗技术有限公司 靶向ror1的抗原结合蛋白
JP2026500705A (ja) * 2022-12-27 2026-01-08 上海医藥集團生物治療技術有限公司 Ｒｏｒ１を標的とする抗原結合タンパク質
CN116183472B (zh) * 2023-04-25 2023-08-18 上海益诺思生物技术股份有限公司 Cba法检测非人类灵长类动物细胞因子的验证方法
WO2025007910A1 (en) * 2023-07-04 2025-01-09 TJ Biopharma (Shanghai) Co., Ltd. Anti-ror1 antibodies and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA114536A (en) 1908-09-18 1908-10-13 Adolphe Chalas Nickel recovering process
CA138293A (en) 1911-11-06 1912-02-06 Charles E. Archie Variable speed gearing
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2003218456A1 (en) 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US20050009136A1 (en) 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
EP2060270A3 (en) 2003-10-16 2009-12-09 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
US10611835B2 (en) 2008-07-10 2020-04-07 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
CA2759733C (en) 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9163258B2 (en) 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
ES2657970T3 (es) 2010-12-01 2018-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos contra ROR1 de conejo/ser humano quiméricos
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
CN103906532B (zh) 2011-08-09 2018-01-26 阿瑟拉生物技术公司 结合磷酰胆碱（pc）和/或pc结合物的抗体
MX353958B (es) 2011-09-22 2018-02-07 Amgen Inc Proteinas de union al antigeno cd27l.
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
WO2014164554A1 (en) 2013-03-10 2014-10-09 Baylor College Of Medicine Chemotherapy-resistant immune cells
WO2016016344A1 (en) 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
HK1243631A1 (zh) 2014-10-27 2018-07-20 Fred Hutchinson Cancer Research Center 用於提高过继细胞免疫疗法效力的组合物和方法
ES2818103T3 (es) 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
WO2016187216A1 (en) 2015-05-18 2016-11-24 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
EP4006056A1 (en) 2016-02-02 2022-06-01 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
CA3024725A1 (en) 2016-06-06 2017-12-14 Juno Therapeutics, Inc. Methods for the treatment of b cell malignancies using adoptive cell therapy

Also Published As

Publication number Publication date
WO2017136607A1 (en) 2017-08-10
US10968275B2 (en) 2021-04-06
EP4006056A1 (en) 2022-06-01
CA3012827A1 (en) 2017-08-10
US20190040132A1 (en) 2019-02-07
CN108699149A (zh) 2018-10-23
JP2019511904A (ja) 2019-05-09
US11932691B2 (en) 2024-03-19
US20210147540A1 (en) 2021-05-20
JP2022028918A (ja) 2022-02-16
ES2903228T3 (es) 2022-03-31
US20240352119A1 (en) 2024-10-24
CN108699149B (zh) 2023-01-06
EP3411408A1 (en) 2018-12-12
EP3411408B1 (en) 2021-12-08
MX2018009011A (es) 2018-11-19
JP7029401B2 (ja) 2022-03-03

Similar Documents

Publication Publication Date Title
US20240352119A1 (en) Anti-ror1 antibodies and uses thereof
KR102056137B1 (ko) 암의 검출 방법
AU2013301341B2 (en) Anti-tumour response to modified self-epitopes
DK2876446T3 (en) Method for detecting cancer
CN118955712A (zh) Cldn 18.2特异性单克隆抗体及其使用方法
TW201922784A (zh) ４﹘１ｂｂ抗體及其製備方法和應用
EP4269436A1 (en) Claudin18.2 chimeric antigen receptor and use thereof
CA2960466C (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
CA2842513A1 (en) Novel anti - cxcr4 antibody and its use for the detection and diagnosis of cancer
EP3239176B1 (en) Anti-active gip antibody
US20240166752A1 (en) Antibody and use thereof
HK40075786A (en) Anti-ror1 antibodies and uses thereof
TW201840588A (zh) 抗ｇｐｒ２０抗體
HK40000385B (en) Anti-ror1 antibodies and uses thereof
KR20210122813A (ko) 항체 및 그의 기능성 단편
WO2026001907A1 (en) Anti-nkg2a antibodies, fusion proteins and uses thereof
WO2025189420A1 (en) Chimeric antigen receptor against programmed deathligand 1 (pd-l1) and application thereof
KR20190107967A (ko) 한국인 위암 연관 유전자 단클론 항체 및 이의 제조방법
JPWO2018034259A1 (ja) Ｔｍｅｍ１３２ａに結合する抗体、抗がん剤、およびがんの検査方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: FRED HUTCHINSON CANCER CENTER

Free format text: FORMER APPLICANT(S): FRED HUTCHINSON CANCER RESEARCH CENTER

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application